分红方面，汉森制药A股上市后累计派现4.85亿元。近三年，累计派现1.51亿元。 机构持仓方面，截止2025年9月30日，汉森制药十大流通股东中，金元顺安元启灵活配置混合 （004685）位居第八大流通股东，持股211.40万股，为新进股东。 12月19日，汉森制药涨2.71%，成交额6621.59万元。两融数据显示，当日汉森制药获融资买入额760.74 万元，融资偿还1092.70万元，融资净买入-331.96万元。截至12月19日，汉森制药融资融券余额合计 1.46亿元。 融资方面，汉森制药当日融资买入760.74万元。当前融资余额1.46亿元，占流通市值的4.25%，融资余 额超过近一年60%分位水平，处于较高位。 融券方面，汉森制药12月19日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，湖南汉森制药股份有限公司位于湖南省益阳市赫山区银城大道2688号，成立日期1998年1月 21日，上市日期2010年5月25日，公司主营业务涉及传统中成药制剂、化学药、医用制剂的研发、生产 和销售 ...

Core Viewpoint - Hansen Pharmaceutical's stock has shown a positive trend with a year-to-date increase of 17.64%, indicating strong market performance and investor interest [2]. Group 1: Stock Performance - As of December 3, Hansen Pharmaceutical's stock price increased by 2.02%, reaching 7.07 CNY per share, with a trading volume of 46.93 million CNY and a turnover rate of 1.35% [1]. - The stock has experienced a 2.61% increase over the last five trading days, a 7.45% increase over the last 20 days, and a 4.74% increase over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Hansen Pharmaceutical reported a revenue of 741 million CNY, reflecting a year-on-year growth of 6.75%. However, the net profit attributable to shareholders decreased by 36.88% to 82.53 million CNY [2]. - The company has distributed a total of 485 million CNY in dividends since its A-share listing, with 151 million CNY distributed over the past three years [3]. Group 3: Business Overview - Hansen Pharmaceutical, established on January 21, 1998, and listed on May 25, 2010, is located in Yiyang, Hunan Province. Its main business includes the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations [2]. - The revenue composition of Hansen Pharmaceutical includes: 54.81% from Si Mo Tang oral liquid, 23.38% from Tian Ma Xing Nao capsules, and smaller contributions from various other products [2]. Group 4: Shareholder Information - As of November 28, 2025, the number of shareholders in Hansen Pharmaceutical increased to 24,100, with an average of 20,618 circulating shares per person, a slight decrease of 0.84% from the previous period [2]. - Among the top ten circulating shareholders, Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund is the eighth largest, holding 2.11 million shares as a new shareholder [3].

Group 1 - The 91st National Pharmaceutical Trade Fair was held in Nanjing from November 19-21, covering over 170,000 square meters with more than 8,200 exhibition booths and over 4,000 domestic and international companies participating [1] - The event featured over 70 forums and activities, with more than 550 industry experts and scholars discussing hot topics and future trends in the pharmaceutical industry [1] - Hunan Hansen Pharmaceutical Co., Ltd., a leading company in Hunan's pharmaceutical sector, showcased its products at the Hunan exhibition area, aiming to promote high-quality development in the industry [1] Group 2 - During the Nanjing Pharmaceutical Trade Fair, Hansen Pharmaceutical's core product, Hansen Si Mo Tang Oral Liquid, was awarded a spot on the "2024-2025 Annual Family Essential Medicine Brand" list due to its excellent efficacy and market reputation [2] - Hansen Pharmaceutical adheres to the corporate value of "treating consumers well and continuously providing good products," aiming to contribute more to the health of the Chinese population [2] - The Si Mo Tang Oral Liquid is a compound traditional Chinese medicine for gastrointestinal motility, included in the national medical insurance catalog and recognized as a protected traditional Chinese medicine product [2]

Company Overview - Hansen Pharmaceutical was established on January 21, 1998, and listed on the Shenzhen Stock Exchange on May 25, 2010. The company is based in Yiyang, Hunan Province, and is a well-known pharmaceutical enterprise in China, focusing on the research and development of traditional Chinese medicine, with its core product, Simiao Decoction Oral Liquid, leading the market share [1] Financial Performance - In the third quarter of 2025, Hansen Pharmaceutical achieved a revenue of 741 million yuan, ranking 47th among 69 industry companies. The industry leader, Baiyunshan, reported a revenue of 61.606 billion yuan, while the second, Yunnan Baiyao, reported 30.654 billion yuan. The industry average revenue was 3.755 billion yuan, with a median of 1.462 billion yuan [2] - The company's net profit for the same period was 82.5252 million yuan, ranking 36th in the industry. The top performer, Yunnan Baiyao, had a net profit of 4.789 billion yuan, and Baiyunshan followed with 3.398 billion yuan. The industry average net profit was 447 million yuan, with a median of 83.6773 million yuan [2] Financial Ratios - Hansen Pharmaceutical's debt-to-asset ratio was 11.77% in the third quarter of 2025, down from 14.33% in the previous year and significantly lower than the industry average of 32.81%. The company's gross profit margin was 77.04%, an increase from 75.13% year-on-year and higher than the industry average of 52.44% [3] Executive Compensation - The chairman and president, Liu Zhengqing, received a salary of 1.7064 million yuan in 2024, an increase of 30,700 yuan from 2023. Liu Zhengqing has a master's degree and has held various positions, including workshop director at Yiyang Pharmaceutical Factory [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders of Hansen Pharmaceutical was 23,300, a decrease of 1.20% from the previous period. The average number of circulating A-shares held per shareholder increased by 1.21% to 21,400 shares. Among the top ten circulating shareholders, Jinyuan Shun'an Yuanqi Flexible Allocation Mixed Fund (004685) was the eighth largest, holding 2.114 million shares as a new shareholder [5]

Group 1 - The core viewpoint of the news is that Hansoh Pharmaceutical's stock performance and financing activities indicate a stable but cautious market position, with significant financing balances and a slight decline in net profit [1][2]. Group 2 - On October 16, Hansoh Pharmaceutical's stock price remained unchanged at 0.00%, with a trading volume of 33.34 million yuan. The financing buy-in amount was 2.92 million yuan, while the financing repayment was 4.74 million yuan, resulting in a net financing buy-in of -1.83 million yuan [1]. - As of October 16, the total financing and securities lending balance for Hansoh Pharmaceutical was 151 million yuan, with the financing balance accounting for 4.61% of the circulating market value, indicating a high level compared to the past year [1]. - In terms of securities lending, there were no shares repaid or sold on October 16, with the securities lending balance also at 0.00 shares, reflecting a high level compared to the past year [1]. Group 3 - Hansoh Pharmaceutical, established on January 21, 1998, and listed on May 25, 2010, specializes in the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations [2]. - The main revenue sources for Hansoh Pharmaceutical include: Si Mo Tang Oral Liquid (54.81%), Tian Ma Xing Nao Capsules (23.38%), and others, with a diverse product portfolio [2]. - As of August 29, the number of shareholders for Hansoh Pharmaceutical was 23,600, a decrease of 3.43% from the previous period, while the average circulating shares per person increased by 3.55% to 21,113 shares [2]. Group 4 - For the first half of 2025, Hansoh Pharmaceutical achieved an operating income of 509 million yuan, representing a year-on-year growth of 5.91%, while the net profit attributable to the parent company was 68.54 million yuan, a decrease of 31.80% year-on-year [2]. Group 5 - Since its A-share listing, Hansoh Pharmaceutical has distributed a total of 485 million yuan in dividends, with 151 million yuan distributed over the past three years [3].

Group 1 - The company, Hansen Pharmaceutical, has confirmed that its product, Si Mo Tang Oral Liquid, has been selected for procurement in multiple projects, including the Beijing-Tianjin-Hebei "3+N" alliance and the fourth batch of centralized procurement in Fujian [2] - The product has also received selected qualification in the fifth round of drug centralized procurement in Jiangsu Province and has limited procurement qualifications in the Guangdong alliance for Jin Lianhua and other traditional Chinese medicine projects [2]

Group 1 - The core viewpoint of the news is that Hansen Pharmaceutical experienced a decline in stock price and significant financing activity on August 29, with a net financing outflow of 475.93 million yuan [1] - On August 29, Hansen Pharmaceutical's financing buy-in amounted to 9.87 million yuan, while the financing repayment was 14.63 million yuan, resulting in a total financing balance of 142 million yuan, which represents 4.19% of its market capitalization [1] - The company has a high financing balance, exceeding the 50th percentile level over the past year, indicating a relatively elevated financing position [1] Group 2 - Hansen Pharmaceutical, established on January 21, 1998, and listed on May 25, 2010, specializes in the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations [2] - The main revenue sources for Hansen Pharmaceutical include Si Mo Tang oral liquid (54.81%), Tian Ma Xing Nao capsules (23.38%), and other products, with a total revenue of 5.09 billion yuan for the first half of 2025, reflecting a year-on-year growth of 5.91% [2] - The net profit attributable to the parent company for the same period was 68.54 million yuan, showing a year-on-year decrease of 31.80% [2] Group 3 - Since its A-share listing, Hansen Pharmaceutical has distributed a total of 485 million yuan in dividends, with 151 million yuan distributed over the past three years [3]

Core Viewpoint - Hansen Pharmaceutical experienced a decline of 4.18% in stock price on August 27, with a trading volume of 131 million yuan, indicating potential market volatility and investor sentiment concerns [1] Financing Summary - On August 27, Hansen Pharmaceutical had a financing buy-in amount of 15.20 million yuan and a financing repayment of 15.99 million yuan, resulting in a net financing buy of -0.797 million yuan [1] - The total financing and securities balance for Hansen Pharmaceutical as of August 27 is 144 million yuan, which accounts for 4.30% of its circulating market value, indicating a relatively high financing level compared to the past year [1] - The company had no short-selling activity on August 27, with a short-selling balance of 0.00 shares, suggesting a lack of bearish sentiment among investors [1] Company Overview - Hansen Pharmaceutical, established on January 21, 1998, and listed on May 25, 2010, is located in Yiyang City, Hunan Province, and specializes in the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations [2] - The company's main revenue sources include: Si Mo Tang Oral Liquid (54.81%), Tian Ma Xing Nao Capsules (23.38%), and other products, with the top three products contributing significantly to total revenue [2] - As of July 31, the number of shareholders increased by 1.15% to 24,400, while the average circulating shares per person decreased by 1.13% to 20,388 shares [2] Financial Performance - For the first half of 2025, Hansen Pharmaceutical reported a revenue of 509 million yuan, reflecting a year-on-year growth of 5.91%, while the net profit attributable to shareholders decreased by 31.80% to 68.54 million yuan [2] - The company has distributed a total of 485 million yuan in dividends since its A-share listing, with 151 million yuan distributed over the past three years [3]

Group 1 - The core viewpoint of the articles highlights the significant progress made by Yiyang City in brand building, with three local brands recognized in national evaluations, indicating a strong competitive advantage in regional branding, traditional industries, and the pharmaceutical health sector [1][2] - The three brands that made the list are Anhua Black Tea, Hunan Shali Socks, and Hunan Hansen Pharmaceutical, showcasing Yiyang's differentiated competitive strengths in their respective fields [1] - Anhua Black Tea ranked 7th in the regional brand category, becoming one of the 36 regional brands with a value exceeding 10 billion yuan, and is positioned as a key player in rural revitalization [1][2] Group 2 - Yiyang's government has implemented a brand-strengthening strategy as a key driver for high-quality economic development, establishing a collaborative mechanism involving government guidance, departmental coordination, enterprise participation, and social involvement [2] - The market regulatory department in Yiyang has focused on enhancing brand value for enterprises by simplifying brand registration processes and providing one-on-one guidance, significantly improving efficiency in brand building [2] - Yiyang has actively promoted quality improvement initiatives, encouraging enterprises to pursue various certifications and providing comprehensive quality management support, which has strengthened brand awareness and contributed to the city's economic development [2]

Core Insights - The company achieved a total revenue of 1.004 billion yuan in 2024, marking a year-on-year growth of 5.12% [1][4] - Net profit attributable to shareholders was 220 million yuan, with a year-on-year increase of 7.43%, but the growth rate significantly slowed compared to 2023 [1][4] - The growth rate of non-recurring net profit dropped from 22.97% in 2023 to 2.89% in 2024, indicating a weakening in the company's profitability excluding non-recurring items [1][4] Revenue and Profit Performance - The company's total revenue surpassed 1 billion yuan for the first time, driven by the sustained promotion of core products and optimization of sales channels [4] - However, the slowdown in net profit growth raises concerns, with a decline from 22.31% in 2023 to 7.43% in 2024 [4] - Rolling quarter-on-quarter data shows total revenue grew by 4.05%, while net profit and non-recurring net profit experienced negative growth of -2.56% and -6.14%, respectively [4] Core Product Performance - Core products such as Si Mo Tang oral liquid and Suo Quan capsules performed well in the market, with Si Mo Tang being a unique product under the national medical insurance directory [4] - The company secured selection in multiple centralized procurement projects, reinforcing its market position [4] - Other products like Suo Quan capsules and Tian Ma Xing Nao capsules have also entered various county-level medical community directories, indicating successful market penetration [4] Market Challenges - The company faces significant market pressure due to deepening medical insurance reforms and the expansion of centralized procurement, which may lead to price reductions and profit margin compression [5] - Ongoing medical anti-corruption efforts impose higher compliance requirements on the company's marketing strategies, making it crucial to maintain competitiveness while adhering to regulations [5] R&D Investment Trends - R&D investment decreased to 39.32 million yuan in 2024, a decline of 7.28% year-on-year, with R&D expenditure accounting for 3.91% of total revenue, down 0.53 percentage points from 2023 [6] - The reduction in R&D spending could hinder the launch of new products and upgrades of existing ones, potentially weakening market competitiveness [6] - Despite some achievements in R&D, such as obtaining registration certificates for certain products, the overall decline in investment raises concerns about future growth [6] Overall Assessment - The company maintained revenue and net profit growth in 2024, but the slowdown in growth rates and decline in R&D investment highlight challenges in adapting to market competition and policy changes [6] - Future strategies should focus on enhancing core product competitiveness, increasing R&D investment, and optimizing cost structures for sustainable development [6]